Amazon launches medication price comparison tools

E-commerce giant Amazon has enabled an online price comparison tool for customers to find and compare the expected price of their medication.

The Amazon Prime prescription savings benefit lets Prime members search for their prescription medication and compare savings at Amazon Pharmacy and other pharmacies that accept the Prime savings card. More than 60,000 pharmacies nationwide are participating, according to Amazon.

Amazon boasts that its Prime prescription savings benefit saves members up to 80% off generic medications and 40% off brand-name medications when customers pay without insurance. In addition, customers can check their insurance co-pay price before they order a medication through Amazon Pharmacy.

“Now we can provide that information quickly, efficiently and entirely online—no need to pick-up the phone to call a pharmacy or insurance provider,” Amazon stated in a blog post announcing the new comparison tools. 

The tool comes as other policies have taken aim at increasing transparency around healthcare prices over the last few years. The Trump administration implemented a new rule that forced hospitals to post their prices online so patients could shop around for the best options. However, the healthcare industry has been slow to adapt to the rule and have pushed back against offering their prices online. A 2020 challenge to the Trump-era rule by the healthcare industry was not granted.

Amazon’s Prime prescription savings benefit is administered by Inside Rx, a company that works directly with pharmaceutical manufacturers and retail pharmacies to find discounts for customers. 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup